Compare Stocks

→ At first glance, this chart looks like nonsense… (From The TradingPub) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PPH VanEck Pharmaceutical ETF	$86.37 -0.6%	$88.75	$74.05 ▼ $91.16	$508.72M	0.72	123,823 shs	91,320 shs
REAL RealReal	$3.45	$3.08	$1.00 ▼ $4.10	$365.53M	2.99	3.34 million shs	1.19 million shs
SOPH SOPHiA GENETICS	$5.06	$4.89	$2.13 ▼ $7.37	$330.06M	1.17	60,155 shs	11,136 shs

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PPH VanEck Pharmaceutical ETF	+1.16%	+2.14%	-2.89%	+3.17%	+9.06%
REAL RealReal	+4.23%	+7.81%	-2.82%	+79.69%	+202.63%
SOPH SOPHiA GENETICS	+1.00%	+1.61%	+5.42%	+6.75%	+5.42%

The system that called 2023’s top 7 stocks is at it again… (Ad)

Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.

Just follow this link here!

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
PPH VanEck Pharmaceutical ETF	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REAL RealReal	0.4427 of 5 stars	1.2	2.0	0.0	0.0	1.9	3.3	0.6
SOPH SOPHiA GENETICS	1.2992 of 5 stars	3.5	3.0	0.0	0.0	1.1	0.0	0.6

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PPH VanEck Pharmaceutical ETF	0.00	N/A	$95.36	10.41% Upside
REAL RealReal	2.33	Hold	$3.61	4.76% Upside
SOPH SOPHiA GENETICS	3.00	Buy	$8.00	58.10% Upside

Current Analyst Ratings

Latest REAL, RKET, PPH, IHP, and SOPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	REAL RealReal	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$2.30 ➝ $3.70
3/6/2024	SOPH SOPHiA GENETICS	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
3/6/2024	SOPH SOPHiA GENETICS	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00
3/1/2024	REAL RealReal	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00

(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PPH VanEck Pharmaceutical ETF	N/A	N/A	N/A	N/A	N/A	N/A
REAL RealReal	$549.30M	0.67	N/A	N/A	($2.97) per share	-1.16
SOPH SOPHiA GENETICS	$62.37M	5.29	N/A	N/A	$3.16 per share	1.60

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PPH VanEck Pharmaceutical ETF	N/A	N/A	20.57	∞	N/A	N/A	N/A	N/A	N/A
REAL RealReal	-$168.47M	-$1.67	N/A	N/A	N/A	-30.67%	N/A	-26.38%	5/7/2024 (Confirmed)
SOPH SOPHiA GENETICS	-$78.98M	-$1.22	N/A	N/A	N/A	-126.63%	-47.40%	-36.43%	5/7/2024 (Confirmed)

Latest REAL, RKET, PPH, IHP, and SOPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2024	N/A	REAL RealReal	-$0.14	N/A	+$0.14	N/A	N/A	N/A
5/7/2024	N/A	SOPH SOPHiA GENETICS	-$0.28	N/A	+$0.28	N/A	N/A	N/A
3/5/2024	12/31/2023	SOPH SOPHiA GENETICS	-$0.25	-$0.37	-$0.12	-$0.37	$16.78 million	$17.05 million
2/29/2024	Q4 2023	REAL RealReal	-$0.19	-$0.15	+$0.04	-$0.09	$142.80 million	$143.37 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
PPH VanEck Pharmaceutical ETF	$1.56	1.81%	N/A	N/A	N/A
REAL RealReal	N/A	N/A	N/A	N/A	N/A
SOPH SOPHiA GENETICS	N/A	N/A	N/A	N/A	N/A

Latest REAL, RKET, PPH, IHP, and SOPH Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
3/28/2024	PPH VanEck Pharmaceutical ETF		$0.5328		4/1/2024	4/2/2024	4/5/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PPH VanEck Pharmaceutical ETF	N/A	N/A	N/A
REAL RealReal	N/A	1.25	1.13
SOPH SOPHiA GENETICS	N/A	4.16	3.97

Ownership

Institutional Ownership

Company	Institutional Ownership
PPH VanEck Pharmaceutical ETF	N/A
REAL RealReal	64.73%
SOPH SOPHiA GENETICS	31.59%

Insider Ownership

Company	Insider Ownership
PPH VanEck Pharmaceutical ETF	N/A
REAL RealReal	9.34%
SOPH SOPHiA GENETICS	4.88%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
PPH VanEck Pharmaceutical ETF	147,000	5.89 million	N/A	Optionable
REAL RealReal	3,032	105.95 million	96.05 million	Not Optionable
SOPH SOPHiA GENETICS	430	65.23 million	62.05 million	Not Optionable

REAL, RKET, PPH, IHP, and SOPH Headlines

Source	Headline
	Member of Kilkenny Live team and his sister taking on massive challenge for DEBRA kilkennypeople.ie - April 23 at 2:08 PM
	Member of Mayo Live team and his sister taking on massive challenge for DEBRA mayonews.ie - April 23 at 2:08 PM
	Short on time? 10 books you can finish quickly. msn.com - April 23 at 2:08 PM
	Brother and sister duo taking on massive challenge for DEBRA limerickleader.ie - April 23 at 2:08 PM
	SOPHiA GENETICS to Announce Financial Results for First Quarter 2024 on May 7, 2024 finance.yahoo.com - April 23 at 2:08 PM
	SOPHiA GENETICS Announces Syndicate Bio as First Liquid Biopsy Customer in Africa prnewswire.com - April 23 at 5:05 AM
	We Think SOPHiA GENETICS (NASDAQ:SOPH) Can Afford To Drive Business Growth finance.yahoo.com - April 21 at 12:15 PM
	Two U Professors Selected as AAAS Fellows healthcare.utah.edu - April 20 at 2:23 PM
	AI In Genomics Market CAGR of 46.0%, Industry Development Scenario, Data Synthesis, Growth Analysis and Regional Overview by 2032 taiwannews.com.tw - April 20 at 2:23 PM
	Sylvester receives grants to study endometrial cancer in Black women communitynewspapers.com - April 20 at 2:23 PM
	Unilabs adopts SOPHiA GENETICS AI for cancer diagnostics investing.com - April 18 at 7:12 PM
	'Shopaholic' author Sophie Kinsella reveals brain cancer diagnosis abcnews.go.com - April 17 at 2:41 PM
	SOPHiA GENETICS SA (NASDAQ:SOPH) Sees Significant Increase in Short Interest americanbankingnews.com - April 15 at 5:40 AM
	Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Expands By 22.3% marketbeat.com - April 13 at 7:47 PM
	RHOC’s Lauri Peterson Shares Glimpse Into ‘Saddest Day of My Life’ After Son Josh Waring’s Death msn.com - April 13 at 6:11 PM
	Leicester girl constantly on sedatives gets 'pacemaker for the brain' msn.com - April 13 at 6:11 PM
	Lauri Peterson Experiences ‘Saddest Day’ After Son Josh Waring’s Death aol.com - April 13 at 1:38 AM
	Emma and other books adapted into both movies and TV shows lifestyleasia.com - April 12 at 8:37 PM
	RBC Capital Sticks to Its Buy Rating for SOPHiA GENETICS (SOPH) markets.businessinsider.com - April 9 at 9:33 AM
	Bill to correct outdated law barring IVF children from inheritance passes committee at eleventh hour enterprise-journal.com - April 4 at 2:09 PM
	SOPHiA GENETICS and Strand Life Sciences Announce New Strategic Partnership prnewswire.com - April 4 at 1:00 AM
	Breast Cancer Outcomes May Be Predicted More Accurately If TILs Serve as Biomarkers genengnews.com - April 3 at 1:46 PM
	Laboratorio Barnafi-Krause is Live on SOPHiA DDM™ prnewswire.com - April 2 at 10:00 AM
	How popular is your dog? These are the top breeds in NJ nj1015.com - March 29 at 2:57 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

5 Stocks in the Current Bull Market with Upside to Come
April 5, 2024 10:14 AM
View 5 Stocks in the Current Bull Market with Upside to Come
Charles Schwab Fortifies its Uptrend on EPS Beat
April 23, 2024 10:15 AM
View Charles Schwab Fortifies its Uptrend on EPS Beat
Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
April 3, 2024 6:20 AM
View Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill
Pagaya Technologies: An AI Fintech That Insiders Are Buying
April 24, 2024 11:12 AM
View Pagaya Technologies: An AI Fintech That Insiders Are Buying
5 Cheap Dividend Stocks: Which to Buy Now
April 1, 2024 9:55 AM
View 5 Cheap Dividend Stocks: Which to Buy Now

All Headlines

Company Descriptions

VanEck Pharmaceutical ETF

NASDAQ:PPH

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.

RealReal

NASDAQ:REAL

The RealReal, Inc. operates an online marketplace for resale luxury goods in the United State. The company offers various product categories, including women's fashion, men's fashion, jewelry, and watches. It primarily sells products through online marketplace and retail stores. The company was incorporated in 2011 and is headquartered in San Francisco, California.

SOPHiA GENETICS

NASDAQ:SOPH

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific. SOPHiA GENETICS SA was incorporated in 2011 and is headquartered in Rolle, Switzerland.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial